Avalo Therapeutics (NASDAQ:AVTX) Price Target Raised to $40.00

Avalo Therapeutics (NASDAQ:AVTX) had its price objective hoisted by HC Wainwright from $25.00 to $40.00 in a research report released on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Avalo Therapeutics’ Q1 2026 earnings at ($1.10) EPS, Q2 2026 earnings at ($1.04) EPS, Q3 2026 earnings at ($0.94) EPS, Q4 2026 earnings at ($0.97) EPS, FY2026 earnings at ($4.02) EPS and FY2027 earnings at ($4.90) EPS.

Other research analysts also recently issued reports about the stock. Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. Guggenheim started coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They issued a “buy” rating and a $50.00 price objective for the company. Finally, BTIG Research reiterated a “buy” rating and set a $40.00 target price on shares of Avalo Therapeutics in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Avalo Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $42.25.

Avalo Therapeutics Stock Down 0.4%

AVTX stock opened at $13.89 on Wednesday. The business has a 50 day moving average price of $15.47 and a 200 day moving average price of $15.78. The stock has a market cap of $316.55 million, a price-to-earnings ratio of -2.42 and a beta of 0.84. Avalo Therapeutics has a fifty-two week low of $3.39 and a fifty-two week high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings results on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($1.54) by $1.17. The company had revenue of $0.06 million during the quarter, compared to analysts’ expectations of ($0.21) million. As a group, sell-side analysts anticipate that Avalo Therapeutics will post -19.07 EPS for the current year.

Insider Activity

In other news, insider Mittie Doyle sold 25,492 shares of Avalo Therapeutics stock in a transaction on Monday, March 16th. The shares were sold at an average price of $16.15, for a total value of $411,695.80. Following the transaction, the insider directly owned 3,622 shares of the company’s stock, valued at $58,495.30. The trade was a 87.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 3.03% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. BIT Capital GmbH acquired a new position in Avalo Therapeutics in the third quarter valued at $25,000. PFS Partners LLC boosted its stake in shares of Avalo Therapeutics by 100.0% during the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock worth $36,000 after buying an additional 1,000 shares during the period. Quadrature Capital Ltd purchased a new position in shares of Avalo Therapeutics during the second quarter worth about $55,000. Boothbay Fund Management LLC purchased a new position in shares of Avalo Therapeutics during the second quarter worth about $56,000. Finally, Dimensional Fund Advisors LP acquired a new position in Avalo Therapeutics in the 3rd quarter valued at about $143,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.